https://www.selleckchem.com/pr....oducts/fetuin-fetal-
Daratumumab is a human monoclonal antibody targeting CD38, an antigen uniformly expressed by plasma cells in multiple myeloma and light chain amyloidosis (AL). We report the results of a prospective multi-center, phase 2 study of daratumumab monotherapy in AL (NCT02816476). Forty previously treated AL patients with a difference between involved and uninvolved free light chains (dFLC) 50 mg/L were included in 15 centers between 9/2016 and 4/2018. Patients received six 28-day cycles of IV daratumumab, QW for cycles
Like
Comment
Share
